Shares of Nanobiotix S.A. (NBTX) are surging more than 100% Friday morning after the company said it is at the final stages of contract negotiations with a major global pharmaceutical company, following agreement to a non-binding term sheet to develop its lead nanotherapeutic candidate NBTXR3.
Nanobiotix said it has agreed to the term sheet as of May 3.
NBTXR3 is currently being evaluated in a Phase 3 study in patients with locally advanced head and neck squamous cell carcinoma (HNSCC).
NBTX is at $4.58. It has traded in the range of $1.75 - $5.82 in the last 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.